سعر نوكتوبكس 2مجم 10 اقراص 2022

Noctopex 2 mg film-coated tablets (Multi-Apex, Egypt): tolterodine L-tartrate 2 mg, an antimuscarinic for overactive bladder; pack of 10.

• Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency in overactive bladder syndromePopulation: Adultselectronic Medicines Compendium (eMC) / MHRA
• Overactive bladder with symptoms of urge urinary incontinence, urgency and frequencyPopulation: AdultsDailyMed (NLM)

• Very common: dry mouth (35% vs 10% placebo) and headache. Common: bronchitis, dizziness, somnolence, paraesthesia, dry eyes, abnormal vision/accommodation, vertigo, palpitations, dyspepsia, constipation, abdominal pain, flatulence, vomiting, diarrhoea, dry skin, dysuria, urinary retention, fatigue, chest pain, peripheral oedema, increased weight.International label, same formulation · electronic Medicines Compendium (eMC) / MHRA
• Uncommon: hypersensitivity, nervousness, memory impairment, tachycardia, cardiac failure, arrhythmia, gastro-oesophageal reflux. Not known: anaphylactoid reactions, confusion, hallucinations, disorientation, flushing, angioedema; aggravation of dementia symptoms in patients on cholinesterase inhibitors.International label, same formulation · electronic Medicines Compendium (eMC) / MHRA

• Urinary retentionInternational label, same formulation · electronic Medicines Compendium (eMC) / MHRA
• Uncontrolled narrow-angle glaucomaInternational label, same formulation · electronic Medicines Compendium (eMC) / MHRA
• Myasthenia gravisInternational label, same formulation · electronic Medicines Compendium (eMC) / MHRA

• Use with caution in significant bladder outlet obstruction (risk of urinary retention), gastrointestinal obstructive disorders (e.g. pyloric stenosis), renal impairment, hepatic disease, autonomic neuropathy, hiatus hernia and risk of decreased gastrointestinal motility.International label, same formulation · electronic Medicines Compendium (eMC) / MHRA
• QTc prolongation was seen with 4 mg and 8 mg daily; use with caution in congenital or acquired QT prolongation, electrolyte disturbances, bradycardia, relevant cardiac disease or with QT-prolonging antiarrhythmics; avoid potent CYP3A4 inhibitors.International label, same formulation · electronic Medicines Compendium (eMC) / MHRA
• Consider organic causes of urge and frequency before treatment.International label, same formulation · electronic Medicines Compendium (eMC) / MHRA

• Potent CYP3A4 inhibitors (e.g. erythromycin, clarithromycin, ketoconazole, itraconazole, antiproteases)Concomitant systemic use not recommended: increased tolterodine serum concentrations in CYP2D6 poor metabolisers with risk of overdosage.electronic Medicines Compendium (eMC) / MHRA
• Other antimuscarinic drugsMay give more pronounced therapeutic and side effects.electronic Medicines Compendium (eMC) / MHRA
• Muscarinic cholinergic receptor agonistsThe therapeutic effect of tolterodine may be reduced.electronic Medicines Compendium (eMC) / MHRA

• No adequate data in pregnant women; animal studies showed reproductive toxicity; not recommended during pregnancy.International label, same formulation · electronic Medicines Compendium (eMC) / MHRA
• No studies in pregnant women; use during pregnancy only if the potential benefit justifies the potential risk to the fetus.International label, same formulation · DailyMed (NLM)
• No data on excretion into human milk; tolterodine should be avoided during lactation.International label, same formulation · electronic Medicines Compendium (eMC) / MHRA

• Tolterodine tartrate: Competitive, specific muscarinic receptor antagonist with selectivity for the urinary bladder over salivary glands in vivo; its 5-hydroxymethyl metabolite has a similar profile.